首页> 外文期刊>EBioMedicine >Combining imaging- and gene-based hypoxia biomarkers in cervical cancer improves prediction of chemoradiotherapy failure independent of intratumour heterogeneity
【24h】

Combining imaging- and gene-based hypoxia biomarkers in cervical cancer improves prediction of chemoradiotherapy failure independent of intratumour heterogeneity

机译:结合宫颈癌中的成像和基因的缺氧生物标志物改善了与肿瘤内异质性无关的化学疗法失败的预测

获取原文
       

摘要

Background Emerging biomarkers from medical imaging or molecular characterization of tumour biopsies open up for combining the two and exploiting their synergy in treatment planning of cancer patients. We generated a paired data set of imaging- and gene-based hypoxia biomarkers in cervical cancer, appraised the influence of intratumour heterogeneity in patient classification, and investigated the benefit of combining the methodologies in prediction of chemoradiotherapy failure. Methods Hypoxic fraction from dynamic contrast enhanced (DCE)-MR images and an expression signature of six hypoxia-responsive genes were assessed as imaging- and gene-based biomarker, respectively in 118 patients. Findings Dichotomous biomarker cutoff to yield similar hypoxia status by imaging and genes was defined in 41 patients, and the association was validated in the remaining 77 patients. The two biomarkers classified 75% of 118 patients with the same hypoxia status, and inconsistent classification was not related to imaging-defined intratumour heterogeneity in hypoxia. Gene-based hypoxia was independent on tumour cell fraction in the biopsies and showed minor heterogeneity across multiple samples in 9 tumours. Combining imaging- and gene-based classification gave a significantly better prediction of PFS than one biomarker alone. A combined dichotomous biomarker optimized in 77 patients showed a large separation in PFS between more and less hypoxic tumours, and separated the remaining 41 patients with different PFS. The combined biomarker showed prognostic value together with tumour stage in multivariate analysis. Interpretation Combining imaging- and gene-based biomarkers may enable more precise and informative assessment of hypoxia-related chemoradiotherapy resistance in cervical cancer. Funding Norwegian Cancer Society , South-Eastern Norway Regional Health Authority, and Norwegian Research Council.
机译:背景从医学成像或肿瘤活检的分子表征的新出现的生物标志物打开了两种,并利用它们在癌症患者治疗计划中的协同作用。我们在宫颈癌中产生了基于成像和基因的缺氧生物标志物的配对数据集,评估了腹腔内的异质性在患者分类中的影响,并研究了将方法组合在化学疗法预测中的益处。方法分别在118例患者中分别评估了动态对比增强(DCE)-MR图像和六种缺氧响应基因的表达特征和六种缺氧响应基因的表达特征。调查结果表明,在41名患者中定义了通过成像和基因产生类似的缺氧状况,并且在剩余的77例患者中验证了该关联。两种生物标志物分类为118名患有相同缺氧状况的75%,分类不一致与缺氧中的成像定义的肿瘤内异质性无关。基于基因的缺氧是独立于活组织检查中的肿瘤细胞级分,并且在9个肿瘤中显示多个样品的轻微异质性。组合成像和基于基因的分类对PFS的显着预测而不是单独的PFS。 77名患者优化的合并二分性生物标志物在较少的缺氧肿瘤之间在PFS中显示出大量分离,并分离剩余的41例不同的PFS患者。组合的生物标志物与多元分析中的肿瘤阶段一起显示了预后值。结合成像和基于基因的生物标志物的解释可以在宫颈癌中对缺氧相关的化学疗法抗性进行更精确和信息性的评估。资助挪威癌症协会,东南部挪威区域卫生管理局和挪威研究理事会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号